BBIO RSI Chart
Last 7 days
3.5%
Last 30 days
20.6%
Last 90 days
-19.0%
Trailing 12 Months
115.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 0 |
2022 | 79.3M | 88.8M | 98.4M | 107.9M |
2021 | 23.6M | 39.0M | 54.3M | 69.7M |
2020 | 0 | 0 | 24.4M | 8.2M |
2019 | 0 | 0 | 0 | 40.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 01, 2024 | scott randal w. | sold | -85,000 | 34.00 | -2,500 | - |
Feb 16, 2024 | homcy charles j | sold (taxes) | -56,149 | 37.21 | -1,509 | - |
Feb 16, 2024 | homcy charles j | acquired | - | - | 3,760 | - |
Feb 16, 2024 | kumar neil | sold (taxes) | -1,783,180 | 37.21 | -47,922 | ceo and president |
Feb 16, 2024 | stephenson brian c | acquired | - | - | 44,996 | secretary, treasurer & cfo |
Feb 16, 2024 | stephenson brian c | sold (taxes) | -703,976 | 37.21 | -18,919 | secretary, treasurer & cfo |
Feb 16, 2024 | kumar neil | acquired | - | - | 102,249 | ceo and president |
Feb 15, 2024 | valantine hannah | sold | -110,041 | 37.75 | -2,915 | - |
Feb 15, 2024 | valantine hannah | acquired | 24,631 | 8.45 | 2,915 | - |
Jan 16, 2024 | valantine hannah | sold | -110,683 | 37.97 | -2,915 | - |
Which funds bought or sold BBIO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Ikarian Capital, LLC | reduced | -40.39 | -10,380,300 | 8,719,840 | 0.96% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 7.27 | -709,116 | 3,265,030 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -582,707 | - | -% |
May 16, 2024 | COMERICA BANK | added | 16,150 | 1,181,290 | 1,190,850 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -2.9 | -2,446,190 | 7,098,490 | -% |
May 16, 2024 | COMERICA BANK | sold off | -100 | -1,206 | - | -% |
May 15, 2024 | IRONWOOD INVESTMENT MANAGEMENT LLC | reduced | -2.25 | -654,489 | 1,949,540 | 0.95% |
May 15, 2024 | D. E. Shaw & Co., Inc. | reduced | -54.82 | -24,415,700 | 12,921,100 | 0.01% |
May 15, 2024 | PORTLAND INVESTMENT COUNSEL INC. | new | - | 905,000 | 905,000 | 0.27% |
May 15, 2024 | FARALLON CAPITAL MANAGEMENT LLC | sold off | -100 | -242,220 | - | -% |
Unveiling Bridgebio Pharma Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bridgebio Pharma Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Bridgebio Pharma Inc News
Income Statement (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 | 2019Q3 |
Revenue | 100.0% | 211 | 106 | - | - | 108 | 60.00 | 13.00 | 2.00 | 54.00 | 27.00 | 0.00 | 8.00 | 17.00 | 27.00 |
Cost Of Revenue | -8.1% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - |
Costs and Expenses | 64.7% | 211 | 128 | 131 | 129 | 154 | 175 | 179 | 152 | 148 | 168 | 128 | 128 | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | 168 | 128 | 128 | 92.00 | 81.00 |
S&GA Expenses | 111.5% | 66.00 | 31.00 | 32.00 | 31.00 | 36.00 | 44.00 | 55.00 | 46.00 | 46.00 | 45.00 | 37.00 | 36.00 | 35.00 | 23.00 |
R&D Expenses | 51.8% | 141 | 93.00 | 91.00 | 93.00 | 108 | 108 | 122 | 104 | 102 | 123 | 90.00 | 92.00 | 57.00 | 55.00 |
EBITDA Margin | - | - | - | - | - | - | - | 7.97* | 10.11* | 14.03* | 23.26* | 65.90* | 7.19* | 7.35* | 1.66* |
Interest Expenses | 16.6% | 23.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 15.00 | 11.00 | 11.00 | 10.00 | 11.00 | 11.00 | 3.00 | 2.00 |
EBT Margin | - | - | - | - | - | - | - | 7.25* | 9.30* | 12.97* | 21.40* | 61.28* | 6.57* | 7.12* | 1.58* |
Net Income | 74.7% | -36.16 | -142 | -140 | -140 | -2.56 | -201 | -152 | -161 | -102 | -171 | -135 | -130 | -84.15 | -60.66 |
Net Income Margin | -28.3% | -5.06* | -3.95* | -4.49* | -5.04* | -5.82* | -7.78* | -8.41* | -10.47* | -13.81* | - | - | - | - | - |
Free Cashflow | -52.6% | -220 | -144 | -94.04 | -135 | -32.85 | -161 | -136 | -128 | -94.00 | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
Assets | 55.4% | 849 | 546 | 655 | 504 | 626 | 623 | 729 | 862 | 813 | 1,013 | 782 | 1,081 | 1,093 | 704 | 788 | 905 | 990 | 632 | 641 | 326 | 465 |
Current Assets | 64.0% | 783 | 478 | 588 | 433 | 553 | 549 | 642 | 771 | 716 | 889 | 640 | 910 | 945 | 643 | 745 | 862 | 925 | 569 | 558 | 307 | 445 |
Cash Equivalents | 26.4% | 475 | 376 | 505 | 302 | 407 | 377 | 483 | 470 | 372 | 394 | 180 | 378 | 471 | 356 | 367 | 541 | 757 | 364 | 414 | 294 | 436 |
Net PPE | -3.4% | 11.00 | 12.00 | 12.00 | 13.00 | 14.00 | 15.00 | 16.00 | 17.00 | 17.00 | 30.00 | 28.00 | 26.00 | 23.00 | 20.00 | 16.00 | 16.00 | 16.00 | 6.00 | 3.00 | 2.00 | 2.00 |
Liabilities | -0.1% | 1,886 | 1,889 | 1,849 | 1,853 | 1,839 | 1,868 | 1,859 | 1,877 | 1,854 | 1,878 | 1,517 | 1,537 | 1,481 | 596 | 569 | 578 | 538 | 156 | 116 | 114 | 88.00 |
Current Liabilities | -1.6% | 141 | 144 | 106 | 110 | 97.00 | 121 | 119 | 141 | 103 | 135 | 96.00 | 132 | 95.00 | 96.00 | 76.00 | 93.00 | 65.00 | 60.00 | 40.00 | 39.00 | 33.00 |
Long Term Debt | -2.6% | 435 | 446 | 442 | 440 | 436 | 431 | - | - | 434 | 431 | 103 | 103 | 91.00 | 92.00 | 93.00 | 93.00 | 92.00 | 92.00 | 75.00 | 75.00 | 55.00 |
LT Debt, Non Current | -100.0% | - | 446 | 442 | 440 | 436 | 431 | - | - | 434 | 431 | 103 | 103 | 91.00 | 92.00 | 93.00 | 93.00 | 92.00 | 92.00 | 75.00 | 75.00 | 55.00 |
Shareholder's Equity | 22.8% | -1,037 | -1,343 | - | - | -1,213 | -1,243 | - | - | - | - | - | - | - | 106 | 216 | 326 | 449 | 474 | 522 | 211 | 377 |
Retained Earnings | -1.4% | -2,595 | -2,560 | -2,392 | -2,215 | -2,057 | -1,918 | -1,780 | -1,643 | -1,633 | -1,436 | -1,289 | -1,133 | -1,037 | -888 | -768 | -652 | -531 | -440 | -366 | -306 | -179 |
Additional Paid-In Capital | 23.0% | 1,821 | 1,481 | 1,460 | 1,128 | 1,107 | 939 | 917 | 893 | 868 | 842 | 821 | 800 | 767 | 1,021 | 1,007 | 993 | 987 | 848 | 826 | 469 | 494 |
Shares Outstanding | 6.9% | 187 | 175 | 174 | 161 | 160 | 151 | 148 | 146 | 146 | 144 | 147 | 143 | - | - | - | - | - | - | - | - | - |
Minority Interest | 8.0% | 12.00 | 11.00 | 12.00 | 12.00 | 12.00 | 11.00 | 10.00 | 12.00 | -0.03 | 3.00 | 5.00 | 7.00 | 6.00 | 48.00 | 52.00 | 60.00 | 68.00 | 65.00 | 62.00 | 48.00 | 62.00 |
Float | - | - | - | - | 2,075 | - | - | - | 977 | - | - | - | 5,000 | - | - | - | 0.00 | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -75.9% | -219,537 | -124,819 | -145,226 | -113,353 | -144,322 | -93,243 | -135,163 | -30,453 | -160,635 | -133,895 | -121,561 | -91,713 | -150,765 | -96,261 | -131,684 | -87,849 | -83,920 | -76,203 | -49,996 | -68,248 | -59,140 |
Share Based Compensation | -53.9% | 17,057 | 37,025 | 22,600 | 27,178 | 21,907 | 21,789 | 17,361 | 28,287 | 24,122 | 19,774 | 16,042 | 30,112 | 33,577 | 12,146 | 17,699 | 18,392 | 10,222 | 10,007 | 5,777 | 3,358 | 2,232 |
Cashflow From Investing | 34574.2% | 22,753 | -66.00 | 37,682 | 4,119 | 12,298 | 17,965 | 146,857 | 149,702 | 138,623 | 21,800 | 58,968 | 458 | -282,052 | 83,018 | -45,050 | -128,984 | 38,023 | -16,901 | -197,342 | -583 | -2,427 |
Cashflow From Financing | 6280.6% | 279,548 | -4,523 | 307,040 | -1,231 | 150,249 | 6,377 | 1,445 | -20,796 | -160 | 325,381 | -135,456 | -1,391 | 547,912 | 4,531 | 2,782 | 703 | 439,173 | 42,904 | 367,508 | -9,969 | -1,651 |
Dividend Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 997 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | 1,542 | 143,150 | 5,308 | 50,000 | - | - | - | 75,000 | - | - | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 211,120 | $ 1,826 |
Operating costs and expenses: | ||
Cost of revenue | 598 | 651 |
Research and development | 140,972 | 92,861 |
Selling, general and administrative | 65,807 | 31,108 |
Restructuring, impairment and related charges | 3,400 | 3,369 |
Total operating costs and expenses | 210,777 | 127,989 |
Income (loss) from operations | 343 | (126,163) |
Other expense, net: | ||
Interest income | 4,075 | 4,153 |
Interest expense | (23,471) | (20,121) |
Loss on extinguishment of debt | (26,590) | 0 |
Other income (expense), net | 9,483 | (601) |
Total other expense, net | (36,503) | (16,569) |
Net loss | (36,160) | (142,732) |
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 944 | 2,576 |
Net loss attributable to common stockholders of BridgeBio | $ (35,216) | $ (140,156) |
Net loss per share attributable to common stockholders of BridgeBio, basic | $ (0.2) | $ (0.92) |
Net loss per share attributable to common stockholders of BridgeBio, diluted | $ (0.2) | $ (0.92) |
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic | 178,705,310 | 152,645,635 |
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted | 178,705,310 | 152,645,635 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 | |||||
---|---|---|---|---|---|---|---|
Current assets: | |||||||
Cash and cash equivalents | $ 475,222 | $ 375,935 | [1] | ||||
Marketable securities | 44,469 | 0 | |||||
Investments in equity securities | 0 | 58,949 | [1] | ||||
Receivables from licensing and collaboration agreements | 235,494 | 1,751 | [1] | ||||
Restricted cash | 131 | 16,653 | [1] | ||||
Prepaid expenses and other current assets | 28,108 | 24,305 | [1] | ||||
Total current assets | 783,424 | 477,593 | [1] | ||||
Property and equipment, net | 11,414 | 11,816 | [1] | ||||
Operating lease right-of-use assets | 8,052 | 8,027 | [1] | ||||
Intangible assets, net | 25,721 | 26,319 | [1] | ||||
Other assets | 20,722 | 22,625 | [1] | ||||
Total assets | 849,333 | 546,380 | [1] | ||||
Current liabilities: | |||||||
Accounts payable | 4,728 | 10,655 | [1] | ||||
Accrued compensation and benefits | 32,395 | 57,370 | [1] | ||||
Accrued research and development liabilities | 40,933 | 29,765 | [1] | ||||
Operating lease liabilities, current portion | 4,544 | 4,128 | [1] | ||||
Deferred revenue, current portion | 13,957 | 6,096 | [1] | ||||
Accrued professional and other accrued liabilities | 44,920 | 35,830 | [1] | ||||
Total current liabilities | 141,477 | 143,844 | [1] | ||||
Term loan, net | 434,717 | 446,445 | [1] | ||||
Operating lease liabilities, net of current portion | 8,297 | 8,981 | [1] | ||||
Deferred revenue, net of current portion | 19,890 | 3,727 | [1] | ||||
Other long-term liabilities | 595 | 5,634 | [1] | ||||
Total liabilities | 1,886,191 | 1,888,915 | [1] | ||||
Commitments and contingencies (Note 8) | |||||||
Redeemable convertible noncontrolling interests | 525 | 478 | |||||
Stockholders’ equity (deficit): | |||||||
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | |||||||
Common stock, $0.001 par value; 500,000,000 shares authorized; 193,314,505 shares issued and 187,122,744 shares outstanding as of March 31, 2024, 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023 | 193 | 181 | [1] | ||||
Treasury stock, at cost; 6,191,761 shares as of March 31, 2024 and December 31, 2023 | (275,000) | (275,000) | [1] | ||||
Additional paid-in capital | 1,820,994 | 1,481,032 | [1] | ||||
Accumulated other comprehensive income | 2 | 31 | [1] | ||||
Accumulated deficit | (2,595,717) | (2,560,501) | [1] | ||||
Total BridgeBio stockholders' deficit | (1,049,528) | (1,354,257) | [1] | ||||
Noncontrolling interests | 12,145 | 11,244 | [1] | ||||
Total stockholders' deficit | (1,037,383) | (1,343,013) | [1],[2] | ||||
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit | 849,333 | 546,380 | [1] | ||||
2029 Notes | |||||||
Current liabilities: | |||||||
Notes, net | 737,392 | 736,905 | [1] | ||||
2027 Notes | |||||||
Current liabilities: | |||||||
Notes, net | $ 543,823 | $ 543,379 | [1] | ||||
|